siRNA (small interfering RNA) is a class of double-stranded RNA molecules typically 21–23 nucleotides in length. Through the RNA interference (RNAi) pathway, siRNA specifically guides the degradation of target mRNA, leading to sequence-specific gene silencing. As one of the most mature small nucleic acid therapeutic platforms, siRNA has demonstrated significant therapeutic potential across multiple disease areas and has become a key modality in nucleic acid drug development.
Leveraging established oligonucleotide chemistry platforms and robust quality control systems, BiOligo provides high-purity siRNA products from nmol to kilogram scale to support nucleic acid drug development. With flexible options for diverse chemical modifications and molecular conjugations, we offer an integrated solution to accelerate small nucleic acid therapeutic development.
Service Specifications
| Product Name | Length | Scale | Purification | Quality Control |
| Custom siRNA Synthesis | 19–30 nt | 2 OD to kilogram scale | RNase-free HPLC Purity ≥90% | HPLC MASS Additional QC requirements |
* For larger-scale production or other customized requirements, please contact blg-mkt@bioligo.com for further consultation.
Delivery Timeline
| OD level | 5–8 days | |
| mg scale | 2 weeks | |
g scale | 2-4 weeks | |
| Above gram scale | Upon consultation | |
Modification Options
Supports over 200+ chemical modifications, including MOE, 2′-O-Methyl, 2′-Fluoro, phosphorothioate (PS), and more.
.png)
Conjugation Options
Supports conjugation with GalNAc, AVβ6, antibodies, cholesterol, and other functional moieties; enables dual-target siRNA design and synthesis.
Gram-Scale Quality Reports
Quality Testing Overview
Test ItemAnalytical MethodRepresentative ResultsValueAppearanceVisual InspectionWhite Solid—Molecular WeightLC-MSWithin ±0.05% of the target molecular weightHigh molecular weight accuracyPurity & Related Substances (Non-Denaturing)IP-RP-HPLC96%–98.27%; AS: 1.39%, SS: 0.11%More reliable drug activity and closer alignment with clinical-stage performancePurity & Related Substances (Denaturing)IP-RP-HPLC90.52%More reliable drug activity and closer alignment with clinical-stage performanceWater ContentKF4.007%High drug yield and cost-effectivenesspH/6.85Close to physiological pH, helping minimize adverse effectsSodium ContentIC/ICP-MS6.0%—Residual SolventsGC0.019%Reduced risk of toxic effectsBacterial EndotoxinsChP/USP0.01–0.1 EU/mgLow endotoxin level, helping reduce immune responses and drug clearanceContent by Weight/95.974%High drug yield and cost-effectivenessReference Reports
Quality Control ReportMass Spectrometry (MS) Analysis
Non-denaturing HPLC AnalysisDenaturing Duplex UPLC Analysis
Water Content DeterminationSodium Content Determination
Residual Solvent DeterminationBacterial Endotoxin Testing
